Longeveron Inc. current report, 16 September 2026

Full document

Business Context and Reporting Period

Longeveron Inc. is a clinical-stage biotechnology company developing cellular therapies for rare pediatric and chronic aging-related conditions. This Form 8-K reports an event dated September 16, 2026, concerning topline results from the Phase 2b ELPIS II trial. The report was signed on September 23, 2026.

Clinical and Key Performance Metrics

  • ELPIS II evaluated laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome.
  • The trial did not meet its primary efficacy endpoint: change from baseline in right ventricular ejection fraction at Month 12.
  • In the intent-to-treat population, the least-squares mean difference between treatment groups was negative 0.7 percentage points.
  • The 95% confidence interval was negative 7.3 to 5.9 percentage points, with p=0.8336.
  • The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.

Material Changes Versus the Prior Comparable Period

The filing does not provide comparative financial statements or a prior-period comparison. The material disclosed development is the negative topline outcome from the ELPIS II clinical trial and failure to achieve its primary efficacy endpoint.

Outlook, Commentary, Risks, and Unusual Items

  • Failure to meet the primary endpoint may adversely affect the prospects, development strategy, regulatory path, and funding requirements for laromestrocel in HLHS.
  • The filing does not state whether additional analyses, follow-up studies, regulatory discussions, or changes to the development program are planned.
  • The filing does not provide updated financial guidance or quantify any expected financial impact.
  • The press release announcing the results is filed as Exhibit 99.1 and incorporated by reference.

Investor Verification Points

  1. Review Exhibit 99.1 for full topline data, secondary endpoints, subgroup analyses, safety results, and management commentary.
  2. Verify the treatment and control group details and the statistical analysis underlying the reported RVEF difference.
  3. Assess whether the company discloses any planned regulatory, clinical, or strategic response to the failed primary endpoint.
  4. Review subsequent filings for impairment charges, financing needs, liquidity changes, or adjustments to the laromestrocel program.